← FDA DRUG APPROVALS
FDA ANDA · ANDA090477
ESCITALOPRAM ORAL SOLUTION
escitalopram oral
Sponsor: CHARTWELL MOLECULAR
APPLICATION
ANDA090477
TYPE
ANDA
ORIGINAL APPROVAL
2013-06-12
LATEST ACTION
2024-03-21
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
ESCITALOPRAM OXALATEPrescription
ESCITALOPRAM OXALATE EQ 5MG BASE/5ML · SOLUTION · ORAL
Approval history
2024-03-21Labeling · Supplement 14 · standardAP
2024-03-20Labeling · Supplement 13 · standardAP
2021-09-21Labeling · Supplement 7 · standardAP
2021-09-08Labeling · Supplement 6 · standardAP
2021-09-08Labeling · Supplement 4 · standardAP
2021-09-08Labeling · Supplement 5 · standardAP
2015-10-23Labeling · Supplement 3 · standardAP
2013-06-12OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.